Pharmaceutical Industry Articles & Reports - Page 43

This article compares the user interfaces of leading conversational AI tools like ChatGPT, Gemini, and Claude, detailing their design, features, and professional impact for business users.

Learn about 21 CFR Part 11, the FDA regulation for electronic records and signatures. Updated for 2026 with the latest FDA guidance on electronic systems, Computer Software Assurance (CSA), and GAMP 5 Second Edition.

Explore Good Manufacturing Practice (GMP) in pharma. Learn its principles, global regulations, implementation, and compliance challenges for quality assurance.

What is GAMP 5? A practical guide to the ISPE framework for computerized system validation: the software categories, the risk-based lifecycle, and how it maps to FDA CSA, 21 CFR Part 11, and EU Annex 11.

Learn what Computer System Validation (CSV) is, its crucial role in pharmaceutical and biotech compliance, ensuring data integrity and regulatory adherence for patient safety.

Compares leading AI OCR models and tools for PDF to structured text conversion in 2026. Examines open-source and commercial solutions including Mistral OCR 3, GPT-4o, and cloud services.

This report details deploying LLMs on 24GB GPUs, covering model architectures, VRAM needs, and optimization methods for efficient local operation.

Learn about meta-prompting, an advanced technique using LLMs to generate, modify, and optimize their own prompts, enabling iterative and complex task execution.

Explore profiles of top global pharmaceutical thought leaders, including their backgrounds, speaking topics, notable engagements, and industry influence.

Learn to build a pharmaceutical manufacturing plant from concept through commissioning. This guide covers planning, regulatory compliance, design, equipment, quality, validation, and approval.

Explore how AI-powered computer vision is transforming pharmaceutical quality control. Review top vendors, applications, and trends in pharma QC automation.

How AI leaders like Amodei, Hassabis, and Huang are accelerating drug discovery, genomics, and life science breakthroughs—compressing decades into years. Updated January 2026 with AlphaFold 3, Claude for Life Sciences, NVIDIA Evo 2, and $3B+ pharma partnerships.

How Veeva Crossix and big data are transforming pharma marketing analytics: capabilities, compliance, case studies, and adoption trends in the U.S.

Comprehensive guide to BI and dashboard tools for pharma: Power BI, Tableau, Qlik, Looker, Domo, Sisense, Strategy (MicroStrategy), IBM Cognos. Updated pricing, compliance, and adoption trends for 2025-2026.

In-depth guide to U.S. pharmaceutical marketing regulations: FDA, FTC, Sunshine Act, anti-kickback, compliance, and IT obligations for pharma companies.

Guide to MarTech API integrations for pharma: CRM, marketing automation, analytics, consent, compliance, and best practices for unified digital engagement.

A practical guide to clinical trial phases 1–3 for pharma IT: objectives, compliance, costs, and IT infrastructure for modern drug development.

Guide to outsourcing HCP marketing in pharma: benefits, risks, industry trends, compliance, and how to manage third-party partnerships effectively.

Best practices for pharma teams to secure first meetings with HCPs: outreach tactics, channel comparison, overcoming gatekeepers, and expert tips for success.

Overview of major HCP data providers, U.S. compliance rules, and best practices for pharma IT. Includes vendor comparison, legal requirements, and governance tips.

How biotech and pharma companies use NetSuite for compliance: FDA 21 CFR Part 11, GxP, HIPAA, SOX, audit trails, e-signatures, and reporting best practices.

Comprehensive comparison of Power BI and Tableau for pharma: features, pricing, compliance, and use cases for IT and analytics teams.

Evidence-based UX strategies for digital HCP engagement platforms in pharma: trends, challenges, best practices, and compliance for IT teams.

A technical comparison of AI agents and AI workflows in pharmaceutical IT, with use cases, pros and cons, and adoption trends for U.S. pharma.